ArticleJournal of the American Heart Association2017
Platelet-Derived Factor V Is a Critical Mediator of Arterial Thrombosis.
Article in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials.Journal of the American Heart Association · 2021Pooled it
- Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.Circulation · 2020Pooled it
- Serum Proteoglycan Alterations Associated with Cardiovascular Risk in Pb-Battery Recycling Workers Using Exploratory Proteomics and Independent ELISA Validation.Cardiovascular toxicology · 2026Article
- Bothrops jararaca snake venom: A reappraisal of its coagulant activity in humans, mice, and rats.PLoS neglected tropical diseases · 2026Article
- A Case of Acquired Factor V Deficiency in a Hemodialysis Patient: A Case Report With Literature Review.IJU case reports · 2026Article
- The role of factor V in trauma-induced coagulopathy: an observational and experimental study.Research and practice in thrombosis and haemostasis · 2025Article
- Review
- Acute Myocardial Infarction in Patients with Hereditary Thrombophilia-A Focus on Factor V Leiden and Prothrombin G20210A.Life (Basel, Switzerland) · 2023Review
- Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.Handbook of experimental pharmacology · 2022Article
- Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis.Frontiers in pharmacology · 2020Article
- Platelet-Derived Factor V Is an Important Determinant of the Metastatic Potential of Circulating Tumor Cells.Frontiers in oncology · 2020Article
- Microfluidic endothelium-on-a-chip development, from in vivo to in vitro experimental models.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie · 2020Article
- Comparative Platelet Releasate Proteomic Profiling of Acute Coronary Syndrome versus Stable Coronary Artery Disease.Frontiers in cardiovascular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoagulation factor V (FV) plays a key role in hemostasis, is present in plasma and platelets, and has both pro- and anticoagulant properties; however, the contribution of platelet-derived FV to arterial thrombosis remains undetermined. METHODS AND
resultsUsing transgenic mice with various levels of FV gene expression that was restricted to the plasma or platelets, the roles of platelet FV were evaluated in the regulation of arterial thrombosis and platelet activation. Mice with higher levels of platelet FV exhibited faster thrombotic occlusion of the carotid artery after injury compared with mice with lower platelet FV levels. Infusion of platelets with higher levels of FV into transgenic mice with undetectable levels of platelet FV reduced the time to carotid artery occlusion. In contrast, infusion of purified recombinant plasma FV into mice with undetectable platelet FV levels failed to reduce the carotid occlusion times following injury. Evaluation of isolated platelets revealed that platelet-derived FV was critical for the regulation of platelet activation. These effects were associated with an increased level of expression of P-selectin and increased cGMP in platelets.
conclusionsWe established that platelet-derived FV is a critical mediator of arterial thrombosis that involves platelet activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.